Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PerkinElmer (NY:PKI)

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, May 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PerkinElmer

< Previous 1 2 3 Next >
PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Launches BioQule NGS System to Automate Library Preparation
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Announces Financial Results for the First Quarter of 2022
From PerkinElmer, Inc.
Via Business Wire
Watch for Continued Gains in Shares of PerkinElmer Inc. (PKI)
Via Investor Brand Network
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Schedules Earnings Call for Tuesday, May 3, 2022
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Expands In Vivo Instruments Portfolio with Hands-free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Introduces First Ready-to-use HTRF® and AlphaLISA® Assay Kits for CHO HCP Impurities Detection and Quantification
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Present at Citi’s 2022 Virtual Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
U.S. Centers for Disease Control Guidance Includes EUROIMMUN Assay in its Two-Step Testing Algorithm for Dengue Virus
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1, 2022
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Present Virtually at J.P. Morgan Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Launches NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 to Strengthen SARS-CoV-2 Surveillance
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Present at 2021 Stifel Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Announces Financial Results for the Third Quarter of 2021
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Releases 2021 Corporate Social Responsibility Report
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Board Declares Quarterly Dividend
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis
From PerkinElmer, Inc. and Honeycomb Biotechnologies, Inc.
Via Business Wire
PerkinElmer Schedules Earnings Call for Tuesday, November 2, 2021
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
From PerkinElmer, Inc.
Via Business Wire
EUROIMMUN Anti-SARS-CoV-2 S1 Curve ELISA Receives FDA Emergency Use Authorization
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Completes Acquisition of Antibody and Reagent Leader BioLegend
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Prices Offering of Senior Notes
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer to Present at 2021 Baird Global Healthcare Conference
From PerkinElmer, Inc.
Via Business Wire
PerkinElmer Announces Financial Results for the Second Quarter of 2021
From PerkinElmer
Via Business Wire
PerkinElmer to Acquire Antibody and Reagent Leader BioLegend
From PerkinElmer, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.